← All trials
NCT05243654
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 1, 2022
- Primary completion
- Aug 31, 2025
- Completion date
- Feb 28, 2026
- First posted
- Feb 17, 2022
- Last posted
- Jul 8, 2022
- Enrollment
- 166
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of OxfordLead sponsor
- Eijkman Institute for Molecular Biology, Jakarta, IndonesiaLead sponsor
- University of LondonCollaborator
- University of OxfordCollaborator
- Government of Papua New GuineaCollaborator
- Radboud UniversityCollaborator
- Diponegoro UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.